Soft multifocal lenses show promise as a management tool for accommodation and vergence disorders in patients without presbyopia.

The VEGA-3 Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia is also enrolling patients. Top-line results are expected in the first half of 2025. The ...

A live audio webcast of the Piper Sandler Healthcare Conference fireside chat can be accessed here and on the LENZ ...

CSF-1 consistently reduces pupil size with an overall gain in near and distance vision when administered to patients with presbyopia. Pilocarpine is a cholinergic muscarinic receptor agonist that ...

Today, with our eyes glued to smartphone and laptop screens 24x7, our vision is continuously subjected to eyestrain and ...

Comfort was the name of the game when OT spoke with contact lens manufacturers and suppliers about recent trends and launches ...

Aceclidine, a pupil-selective miotic, is well tolerated and significantly improves near vision in patients with presbyopia, according to research presented at the American Academy ...

It is driven by the rising prevalence of these vision conditions. The global myopia and presbyopia treatment market is set to ...

The "Myopia and Presbyopia Treatment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's ...

Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics' Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. Following prepared remarks from ...

In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...

CORXEL and LENZ Therapeutics announced positive topline data from Phase 3 study in China for the treatment of presbyopia Cash ...